Biocept expands commercial availability of CSF assay to metastatic melanoma

Cancer Cell Target2

Molecular diagnostics firm Biocept said on Monday that it is expanding the commercial availability of its CNSide assay to include the detection of metastatic melanoma.

CNSide is a cerebrospinal fluid (CSF) assay to detect and inform treatment decisions for patients with metastatic cancers involving the central nervous system.

The assay has already been validated for the detection of lung, breast, and other carcinomas, the firm said.

The new CNSide for melanoma assay uses an antibody cocktail optimized for the capture of melanoma cells based on unique cellular characteristics.

“Our early development experience evaluating patients with melanoma with CNSide is similar to what we have seen in carcinomas, supporting the expanded clinical use of this CLIA laboratory developed test,” Dr. Michael Dugan, chief medical officer and medical director at Biocept, said in a statement. 

Page 1 of 170
Next Page